In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|November 19, 2020
Almac Group Receives Award from COVID-19 Therapeutics Accelerator to Produce Remdesivir
Author(s)BioPharm International Editors
Almac Sciences has been granted an award by the COVID-19 Therapeutics Accelerator for the development of an efficient and scalable production process for remdesivir.
Advertisement
Almac Sciences, a member of Almac Group, has been granted an award worth US $500,000 by the COVID-19 Therapeutics Accelerator for the development of an efficient and scalable production process for remdesivir.
According to a Nov. 17, 2020 press release, the funding will enable Almac Sciences to apply its plan to improve the overall route of synthesis to remdesivir, including application of synthetic flow methodology and biocatalysis. This plan will ultimately lower raw material usage, increase global yields, and lower the overall cost of goods for the remdesivir development process.
“We are delighted to receive funding from the Therapeutics Accelerator to apply our skills in the fight against COVID-19,” said Dr. Stefan Mix, head of Biocatalysis, Almac Sciences, in the press release. “With the skillset of our multidisciplinary teams, we are confident that our developmental approach to the manufacture of remdesivir will positively impact patients’ lives who are in urgent need, regardless of their location.”
“This project highlights Almac’s strength in technology deployment through application of both innovative flow chemistry and biocatalysis technologies to support development of processes which are economical, greener, and safer to perform,” added Prof. Tom Moody, vice-president of Technology Development and commercialization at Almac Sciences and Arran Chemical Company, in the press release.
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
5